Pradaxa is a prescription blood thinner designed to reduce the risk of blood clots and stroke. The Food and Drug Administration (FDA) approved Pradaxa for use in consumers in October 2010. Since then, patients taking Pradaxa have come forward with complaints and lawsuits regarding the drug’s apparent connection to serious health risks and complications – including wrongful death.
If you or a loved has suffered adverse events after taking Pradaxa, contact our attorneys. This anticoagulant may be unsafe for consumers, and you may have grounds for a lawsuit against the manufacturer, Boehringer Ingelheim. The Dickerson Oxton Law Firm can review your case and help you discover if you have the elements of a personal injury claim. If so, you could be eligible for significant compensation.
Why Choose Us?
The lawyers at the Dickerson Oxton Law Firm have extensive experience handling defective drug and medical devices cases in the U.S. We have the resources, education, and in-depth knowledge about Pradaxa and other dangerous blood thinners to help injured patients.
Clients trust us with their claims because:
- We do not charge anything unless we win financial compensation for clients.
- We believe in personalized, client-centered legal services.
- We dedicate our firm to obtaining justice for injured and wronged patients.
- We have hands-on experience going up against Big Pharma companies during trials.
If you have grounds for a product liability lawsuit against Boehringer Ingelheim (the maker of Pradaxa), our firm is the right choice for your legal representation. We can review your case, file a lawsuit on your behalf, and argue for fair compensation based on your damages.
What Is Pradaxa? What Are the Issues?
Pradaxa is a potentially deadly blood thinner that patients have linked to severe bleeding events, internal hemorrhaging, and wrongful death. Manufactured to help patients at risk of blood clots and pulmonary embolisms, Pradaxa may pose more risks than rewards for those who take the drug. Rather than the safe anticoagulant the manufacturer marketed, patients are suffering serious personal injuries and health complications from a drug that appears to cause dangerous side effects.
For the first five years after Pradaxa’s release, there was no antidote to the uncontrolled bleeding events many patients experienced. This unfortunately made these events deadly for thousands of victims. Although today an antidote exists that can reverse the bleeding effects of the drug, patients can still suffer adverse health effects, significant blood loss, and related injuries and damages from taking Pradaxa.
So far, thousands of patients have filed lawsuits against Boehringer Ingelheim for alleged product liability. These lawsuits state that the drug maker should have warned consumers of the high risk for severe bleeding. In 2014, the federal courts made Boehringer Ingelheim pay $650 million to settle around 4,000 lawsuits involving the drug. Since then, another round of class action lawsuits has arisen from claimants who did not participate in the first litigation.
Potential Compensation Options
Patients injured by Pradaxa may qualify for financial compensation from the federal courts. Successful claims can lead to payment for victims’ past and future Pradaxa-related medical expenses, pain and suffering, lost wages, lost enjoyment of life, legal fees, and other damages. Claimants who lost loved ones because of the dangers of Pradaxa may also be eligible to receive wrongful death damages, including reasonable payment for funeral and burial expenses.
Contact Us Today
If you or a family member suffered from uncontrollable bleeding or other adverse events after taking the blood thinner Pradaxa, contact the Dickerson Oxton Law Firm. Our lawyers will listen to your story, let you know if we think it has merit, and potentially help you file your individual lawsuit or class action against the drug manufacturer in pursuit of damages. We can walk you through every step of the legal process. Call (816) 268-1960 today to request your free consultation in Kansas City.